T/CAPC 012-2023 Active Group standards

T/CAPC 012-2023 Retail pharmacy operation for diabetes, hypertension and lipid disorder treatment with pharmaceutical services specifications for pharmacy practice

Publish Date: 2023-11-29 Implement Date: 2023-11-29 For services related to genuine standard inquiry, procurement, translation, and other related services in China, please Contact Us

Price: $ 20.00

Download

Basic Information

Standard Code: T/CAPC 012-2023

Standard Type: Group standards

Standard Status: Active

is_force_gb: no

CCS Name: -

ICS Name: Integrated services

Publish Date: 2023-11-29

Implement Date: 2023-11-29

Pages: 19 pages

Scope

Scope: This document is applicable to retail pharmacies providing pharmaceutical services for patients with diabetes, hypertension, and dyslipidemia (hereinafter referred to as "the three highs"). The pharmaceutical service targets patients with a clear diagnosis of the three highs who receive home-based drug treatment. Main technical content: Retail pharmacies should fully recognize that the three highs in China are the three main risk factors for the incidence and mortality of cardiovascular diseases. Based on the characteristics of a large number of patients with the three highs in China and a low control rate, retail pharmacies should give full play to their role in chronic disease management and provide standardized, continuous, and full-course pharmaceutical services for patients with the three highs. By collecting patient information, evaluating interventions, providing medication guidance, patient education, home follow-ups, and establishing medical records, pharmacies can enhance patients' correct understanding of the disease and medication adherence, improve their self-management ability and develop good living habits, reduce the overall risk of cardiac, cerebral, renal, and vascular complications and mortality in patients with the three highs, and improve their quality of life.